Suchergebnisse - "Lauseker, Michael"

PubPharm (11)

1

SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment

enthalten in: Leukemia & lymphoma | 2022

von Egeli, D. | Hanfstein, B. | Lauseker, M. | +4

2

Imatinib dose reduction in major molecular response of chronic myeloid leukemia : results from the German Chronic Myeloid Leukemia-Study IV

enthalten in: Haematologica | 2019

von Michel, C. | Burchert, A. | Hochhaus, A. | +58

CommentIn: Haematologica. 2019 May;104(5):862-864. - PMID 31040230

3

Defining therapy goals for major molecular remission in chronic myeloid leukemia : results of the randomized CML Study IV

enthalten in: Leukemia | 2018

von Saussele, S. | Hehlmann, R. | Fabarius, A. | +21

4

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia : results of the randomized CML study IV

enthalten in: Blood | 2015

von Saussele, S. | Krauss, M. | Hehlmann, R. | +31

CommentIn: Blood. 2015 Jul 2;126(1):2-4. - PMID 26138535

5

A multi-state model approach for prediction in chronic myeloid leukaemia

enthalten in: Annals of hematology | 2015

von Lauseker, M. | Hasford, J. | Hoffmann, V. | +4

6

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

enthalten in: Haematologica | 2014

von Hanfstein, B. | Lauseker, M. | Hehlmann, R. | +27

7

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients : a subanalysis of the randomized CML-Study IV

enthalten in: Annals of hematology | 2014

von Proetel, U. | Pletsch, N. | Lauseker, M. | +124

8

The impact of health care settings on survival time of patients with chronic myeloid leukemia

enthalten in: Blood | 2014

von Lauseker, M. | Hasford, J. | Pfirrmann, M. | +2

9

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib : results from the randomized CML-study IV

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Hehlmann, R. | Müller, M. | Lauseker, M. | +29

CommentIn: J Clin Oncol. 2014 Feb 10;32(5):471-4. - PMID 24297955

10

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2011

von Hehlmann, R. | Lauseker, M. | Jung-Munkwitz, S. | +17

CommentIn: J Clin Oncol. 2011 Apr 20;29(12):1512-6. - PMID 21422414